Hirva Mamdani, MD

Hirva Mamdani, MD, discusses the rationale to evaluate the immunogenicity of STK11 and TP53 co-mutations in non–small cell lung cancer.

Hirva Mamdani, MD, discusses the need to develop novel therapies in locally advanced esophageal and gastroesophageal junction adenocarcinoma.